⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315195 | 0.67 | MAPT (0.35) | — | |
| SCHEMBL378443 | 0.62 | — | — | |
| SCHEMBL16597554 | 0.60 | MAPT (0.36) | — | |
| SCHEMBL83270 | 0.55 | — | — | |
| SCHEMBL1975337 | 0.54 | MAPT (0.44) | — | |
| SCHEMBL451181 | 0.53 | — | — | |
| SCHEMBL855749 | 0.52 | — | — | |
| SCHEMBL3450207 | 0.52 | — | — | |
| SCHEMBL14511179 | 0.52 | MAPT (0.68) | — | |
| Benzimidazole SCHEMBL29406970 | 0.50 | SMN1; SMN2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | NOVARTIS AG | 2010-01-28 | — | — | US | claimed |
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | claimed |
| EP-1968954-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | claimed |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | claimed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | claimed |
| WO-2007077004-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | claimed |
| JP-2007510002-A | — | — | 2007-04-19 | — | — | JP | claimed |
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2007-03-29 | — | — | US | claimed |
| EP-1682521-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2006-07-26 | — | — | EP | claimed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | claimed |
| WO-2005049585-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | claimed |
| EP-3247701-B1 | ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-09-22 | — | — | EP | disclosed |
| US-10597364-B2 | Anthelmintic compounds, compositions and method of using thereof | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180009754-A1 | ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| EP-3247701-A1 | ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF | Merial, Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-2007077004-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2007-03-29 | — | — | US | disclosed |
| EP-1682521-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005049585-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |